Drug Trial Radar · NCT00848549
Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures
Last checked: Nov 20, 2026Latest source record: Dec 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
295
Actual
Start
Oct 2008
Primary completion
Jun 2011
Study completion Nov 2011
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Feb 20, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 78 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the long-term safety and tolerability and to explore the long-term efficacy of zonisamide as monotherapy treatment in subjects with newly diagnosed partial seizures.
Conditions
- Epilepsy
Interventions
ZonisamideDrug
Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
CarbamazepineDrug
Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Remaining in the Study at Each VisitTime frame: At 3, 6, 9, 12, 15, 18, 21, 24, and 27 months
Locations
133 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Queensland, Australia
Site not named
Camperdown, New South Wales, Australia
Site not named
Bedford Park, South Australia, Australia
Site not named
Clayton, Victoria, Australia
Site not named
Fitzroy, Victoria, Australia
Site not named
Heidelberg West, Victoria, Australia
Site not named
Parkville, Victoria, Australia
Site not named
Perth, Western Australia, Australia
Site not named
Aalborg, Denmark
Site not named
Béthune, France
Site not named
Dijon, France
Site not named
Paris, France
Site not named
Saint-Etienne, France
Site not named
Berlin, Germany
Site not named
Bochum, Germany
Site not named
Düsseldorf, Germany
Site not named
Munich, Germany
Site not named
Schwerin, Germany
Site not named
Westerstede, Germany
Site not named
Athens, Greece
Site not named
Athens, Greece
Site not named
Athens, Greece
Site not named
Pátrai, Greece
Site not named
Thessaloniki, Greece
Site not named
Thessaloniki, Greece
Site not named
Thessaloniki, Greece
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Debrecen, Hungary
Site not named
Gyula, Hungary
Site not named
Hódmezővásárhely, Hungary
Site not named
Nyregyhaza, Hungary
Site not named
Zalaegerszeg-Poozva, Hungary
Site not named
Bangalore, India
Site not named
Bangalore, India
Site not named
Hyderabad, India
Site not named
Koturpuram, Chennai, India
Site not named
Madurai, Tamil Nadu, India
Site not named
Mumbai, India
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.